<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Abstract Calcitonin gene-related peptide (CGRP) is a major player in" exact="migraine" post="pathophysiology, and CGRP monoclonal antibodies including fremanezumab may be"/>
 <result pre="a safe effective preventive therapy. Phase IIb studies in episodic" exact="migraine" post="(EM) and chronic migraine (CM) demonstrated efficacy at both"/>
 <result pre="therapy. Phase IIb studies in episodic migraine (EM) and chronic" exact="migraine" post="(CM) demonstrated efficacy at both the monthly 225 mg"/>
 <result pre="both showed a reduction in the primary endpoint of monthly" exact="migraine" post="days (MMD). In the EM trial, the baseline MMD"/>
 <result pre="for EM and CM fremanezumab is a new option for" exact="migraine" post="preventive treatment. Keywords fremanezumab migraine headache calcitonin gene-related peptide,"/>
 <result pre="is a new option for migraine preventive treatment. Keywords fremanezumab" exact="migraine" post="headache calcitonin gene-related peptide, CGRP treatment monoclonal antibody table-count:"/>
 <result pre="peptide (CGRP) is believed to play a major role in" exact="migraine" post="pathophysiology. Evidence to date suggests that inhibition of CGRP"/>
 <result pre="threshold trigeminovascular neurons being activated and/or sensitized hence preventing the" exact="migraine" post="pain phase. 4 The half-life has been reported in"/>
 <result pre="studies, as well as the inclusion of patients with chronic" exact="migraine" post="(CM) and medication overuse (MO), also raise the question"/>
 <result pre="September 14, 2018 with the indication of preventive treatment for" exact="migraine" post="in adults. Fremanezumab in clinical trials A Phase IIb"/>
 <result pre="in clinical trials A Phase IIb study of high-frequency episodic" exact="migraine" post="(HFEM) in 297 patients looked at both 225 and"/>
 <result pre="placebo for primary and secondary endpoints of change in monthly" exact="migraine" post="days (MMD) and in headache days from baseline at"/>
 <result pre="wk 675 mg q12 wk Placebo 12 weeks Mean monthly" exact="migraine" post="days 225 mg: −3.7 675 mg: −3.4 Placebo: −2.2"/>
 <result pre="wk Placebo Every 4 weeks for 12 weeks Mean monthly" exact="migraine" post="days 675/225: −4.6 675: −4.3 Placebo: −2.5 Notes: aInjection"/>
 <result pre="compared to placebo of −2.2 days. A reduction in acute" exact="migraine" post="medication (all types) was also assessed with a 3-day"/>
 <result pre="and 18% for placebo (both p&amp;lt;0.001). The use of acute" exact="migraine" post="treatment was reduced by 4.2 days in monthly fremanezumab,"/>
 <result pre="a patient with previously unreported Ehlers-Danlos syndrome and another was" exact="glaucoma" post="with increased intra-ocular pressure 84 days after treatment. 21"/>
 <result pre="was injection site reaction. There were three patients with drug" exact="hypersensitivity" post="of which two were on placebo. Respiratory events were"/>
 <result pre="drug exposure, and cause of death was determined to be" exact="chronic obstructive pulmonary disease." post="18 The most common adverse events reports were injection"/>
 <result pre="There were reports of upper respiratory tract infections (4%) and" exact="nasopharyngitis" post="(4%). Unlike erenumab, constipation has not been reported as"/>
 <result pre="upper respiratory tract infections (4%) and nasopharyngitis (4%). Unlike erenumab," exact="constipation" post="has not been reported as a common adverse effect"/>
 <result pre="ischemic attack, three deep vein thromboses, and one new onset" exact="atrial fibrillation." post="Safety with fremanezumab in cardiac patients has not been"/>
 <result pre="data demonstrated &amp;lt;1% ophthalmologic disorders. Specific cases described included bilateral" exact="retinal detachment" post="after fremanezumab 675 mg and vitreous detachment after 2"/>
 <result pre="described included bilateral retinal detachment after fremanezumab 675 mg and" exact="vitreous detachment" post="after 2 doses of fremanezumab 675 mg (taken monthly)."/>
 <result pre="were also reported as well as individual cases of unilateral" exact="retinal detachment," post="vitreous detachment, vitreous prolapse, and unilateral vision loss. The"/>
 <result pre="reported as well as individual cases of unilateral retinal detachment," exact="vitreous detachment," post="vitreous prolapse, and unilateral vision loss. The direct correlation"/>
 <result pre="also raises the question of safety in the setting of" exact="stroke" post="– could a transient ischemic attack or minor stroke"/>
 <result pre="of stroke – could a transient ischemic attack or minor" exact="stroke" post="be converted to a larger more debilitating stroke with"/>
 <result pre="or minor stroke be converted to a larger more debilitating" exact="stroke" post="with these agents? The same question is raised for"/>
 <result pre="these agents? The same question is raised for those with" exact="unstable angina" post="and the risk of myocardial infarction. The long-term effects"/>
 <result pre="this neuropeptide that has been shown to be integral to" exact="migraine" post="pathophysiology. At this time, the prophylactic effects in EM"/>
 <result pre="at least 18 years of age with a diagnosis of" exact="migraine" post="with or without aura. In those with a low"/>
 <result pre="has benefit for not only complex patients but the entire" exact="migraine" post="population with indication for prophylaxis. Further post-market studies are"/>
 <result pre="monoclonal CGRP antibody in development for the preventive treatment of" exact="migraine" post=". Curr Pain Headache Rep . 2015; 19( 3):"/>
 <result pre="al. Fremanezumab as add-on treatment for patients treated with other" exact="migraine" post="preventive medicines . Headache . 2017; 57( 9): 1375–"/>
 <result pre=", McDonald M , Dodick DW . Sustained reductions in" exact="migraine" post="days, moderate-to-severe headache days and days with acute medication"/>
 <result pre=", et al. Efficacy of fremanezumab in patients with chronic" exact="migraine" post="who had prior use of topiramate or onabotulinumtoxinA (P4.104)"/>
 <result pre="as a function of triptan use among individuals with chronic" exact="migraine" post="(P2.205) . Neurology . 2016; 86( 16 Supplement): P2.205."/>
 <result pre=". The American Headache Society position statement on integrating new" exact="migraine" post="treatments into clinical practice . Headache . 2019; 59("/>
</results>
